• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨桥蛋白作为自噬的负调节剂,在非酒精性脂肪性肝病的发展过程中加速脂质堆积。

Osteopontin acts as a negative regulator of autophagy accelerating lipid accumulation during the development of nonalcoholic fatty liver disease.

机构信息

Division of Gastroenterology and Hepatology, Institution of Digestive Diseases, Tongji Hospital, Tongji University School of Medicine, Shanghai, P. R. China.

出版信息

Artif Cells Nanomed Biotechnol. 2020 Dec;48(1):159-168. doi: 10.1080/21691401.2019.1699822.

DOI:10.1080/21691401.2019.1699822
PMID:31852298
Abstract

Accumulating evidence links osteopontin (OPN), a pro-fibrogenic extracellular matrix protein, to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). In this study, liver tissues isolated from non-alcoholic steatohepatitis (NASH) patients expressed higher OPN than those of controls. However, the exact mechanism(s) for this phenomenon is yet to be clarified. Autophagy is the natural, regulated degradation and recycling of a cell's dysfunctional components, in order to maintain homeostasis. Increasing evidence supports that autophagy can constitute an effective Defence mechanism against NAFLD conditions. Herein, we constructed NAFLD mice model by high-fat (HF) and methionine-choline-deficient (MCD) diet and found that OPN is upregulated in livers of NAFLD mice. Besides, secreted OPN inhibited autophagosome-lysosome fusion via binding with its receptors integrin αVβ3 and αVβ5 in HepG2 cells supplemented with free fatty acids (FFA) and the livers of NAFLD mice. Silencing of OPN attenuated autophagy impairment and reduced lipid accumulation, while supplementation of OPN exhibited the opposite effect. Furthermore, treatment with anti-OPN Ab significantly attenuated steatosis as well as autophagy impairment in the liver. Our findings indicated that OPN plays a vital role in the pathogenesis of the development of NAFLD via autophagy impairment, which might represent a potential new therapeutic target for the treatment of NAFLD.

摘要

越来越多的证据表明,骨桥蛋白(OPN)是一种促纤维化细胞外基质蛋白,与非酒精性脂肪性肝病(NAFLD)的发病机制有关。在这项研究中,非酒精性脂肪性肝炎(NASH)患者的肝组织表达的 OPN 高于对照组。然而,这种现象的确切机制尚不清楚。自噬是细胞内功能失调成分的自然、调节性降解和再循环,以维持细胞内环境稳定。越来越多的证据支持自噬可以构成对抗 NAFLD 条件的有效防御机制。在此,我们通过高脂肪(HF)和蛋氨酸-胆碱缺乏(MCD)饮食构建了 NAFLD 小鼠模型,发现 OPN 在 NAFLD 小鼠的肝脏中上调。此外,在补充游离脂肪酸(FFA)的 HepG2 细胞和 NAFLD 小鼠的肝脏中,分泌的 OPN 通过与其受体整合素αVβ3 和αVβ5 结合,抑制自噬体-溶酶体融合。沉默 OPN 可减轻自噬损伤和减少脂质积累,而补充 OPN 则表现出相反的效果。此外,抗 OPN Ab 的治疗可显著减轻肝脏的脂肪变性和自噬损伤。我们的研究结果表明,OPN 通过自噬损伤在 NAFLD 的发病机制中起着重要作用,这可能代表了治疗 NAFLD 的一个潜在新的治疗靶点。

相似文献

1
Osteopontin acts as a negative regulator of autophagy accelerating lipid accumulation during the development of nonalcoholic fatty liver disease.骨桥蛋白作为自噬的负调节剂,在非酒精性脂肪性肝病的发展过程中加速脂质堆积。
Artif Cells Nanomed Biotechnol. 2020 Dec;48(1):159-168. doi: 10.1080/21691401.2019.1699822.
2
Rubicon inhibits autophagy and accelerates hepatocyte apoptosis and lipid accumulation in nonalcoholic fatty liver disease in mice.鲁比卡丁抑制自噬,促进非酒精性脂肪性肝病小鼠肝细胞凋亡和脂质蓄积。
Hepatology. 2016 Dec;64(6):1994-2014. doi: 10.1002/hep.28820. Epub 2016 Oct 21.
3
The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression.转录因子 c-Jun/AP-1 通过调节骨桥蛋白表达促进非酒精性脂肪性肝炎肝纤维化。
Cell Death Differ. 2019 Sep;26(9):1688-1699. doi: 10.1038/s41418-018-0239-8. Epub 2019 Feb 18.
4
Significance of MR/OPN/HMGB1 axis in NAFLD-associated hepatic fibrogenesis.MR/OPN/HMGB1 轴在非酒精性脂肪性肝病相关肝纤维化中的意义。
Life Sci. 2021 Jan 1;264:118619. doi: 10.1016/j.lfs.2020.118619. Epub 2020 Oct 20.
5
Osteopontin is a proximal effector of leptin-mediated non-alcoholic steatohepatitis (NASH) fibrosis.骨桥蛋白是瘦素介导的非酒精性脂肪性肝炎(NASH)纤维化的近端效应因子。
Biochim Biophys Acta. 2016 Jan;1862(1):135-44. doi: 10.1016/j.bbadis.2015.10.028. Epub 2015 Oct 31.
6
Involvement of G protein-coupled receptor kinase 2 (GRK2) in the development of non-alcoholic steatosis and steatohepatitis in mice and humans.G 蛋白偶联受体激酶 2(GRK2)在小鼠和人类非酒精性脂肪性肝病和脂肪性肝炎发生发展中的作用。
Biochim Biophys Acta Mol Basis Dis. 2018 Dec;1864(12):3655-3667. doi: 10.1016/j.bbadis.2018.09.027. Epub 2018 Sep 24.
7
NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease.NKT 相关的 hedgehog 和骨桥蛋白驱动非酒精性脂肪性肝病中的纤维化。
Gut. 2012 Sep;61(9):1323-9. doi: 10.1136/gutjnl-2011-301857. Epub 2012 Mar 17.
8
Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis.美罗华醇在非酒精性脂肪性肝炎中的治疗效果及自噬调控作用。
Lipids Health Dis. 2019 Oct 21;18(1):179. doi: 10.1186/s12944-019-1118-0.
9
Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis.骨桥蛋白受 hedgehog 通路激活诱导,并促进非酒精性脂肪性肝炎纤维化进展。
Hepatology. 2011 Jan;53(1):106-15. doi: 10.1002/hep.23998. Epub 2010 Oct 21.
10
Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice.生长分化因子 15 可改善小鼠的非酒精性脂肪性肝炎及相关代谢紊乱。
Sci Rep. 2018 May 1;8(1):6789. doi: 10.1038/s41598-018-25098-0.

引用本文的文献

1
Osteokines in Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病中的成骨细胞因子。
Curr Obes Rep. 2024 Dec;13(4):703-723. doi: 10.1007/s13679-024-00586-9. Epub 2024 Sep 3.
2
Extracellular vesicles-derived ferritin from lipid-induced hepatocytes regulates activation of hepatic stellate cells.脂质诱导的肝细胞来源的细胞外囊泡铁蛋白调节肝星状细胞的激活。
Heliyon. 2024 Jun 27;10(13):e33741. doi: 10.1016/j.heliyon.2024.e33741. eCollection 2024 Jul 15.
3
Black phosphorus quantum dots prevent atherosclerosis in high-fat diet-fed apolipoprotein E knockout mice.
黑磷量子点可预防高脂饮食喂养的载脂蛋白 E 基因敲除小鼠的动脉粥样硬化。
Aging (Albany NY). 2024 Jul 10;16(13):10784-10798. doi: 10.18632/aging.205874.
4
Causal effects of non-alcoholic fatty liver disease on osteoporosis: a Mendelian randomization study.非酒精性脂肪性肝病对骨质疏松症的因果影响:一项孟德尔随机化研究。
Front Endocrinol (Lausanne). 2023 Dec 12;14:1283739. doi: 10.3389/fendo.2023.1283739. eCollection 2023.
5
Peroxisomal defects in microglial cells induce a disease-associated microglial signature.小胶质细胞中的过氧化物酶体缺陷会诱发一种与疾病相关的小胶质细胞特征。
Front Mol Neurosci. 2023 Apr 17;16:1170313. doi: 10.3389/fnmol.2023.1170313. eCollection 2023.
6
Liver-bone crosstalk in non-alcoholic fatty liver disease: Clinical implications and underlying pathophysiology.非酒精性脂肪性肝病中的肝-骨串扰:临床意义和潜在病理生理学。
Front Endocrinol (Lausanne). 2023 Mar 10;14:1161402. doi: 10.3389/fendo.2023.1161402. eCollection 2023.
7
Osteopontin Promotes Macrophage M1 Polarization by Activation of the JAK1/STAT1/HMGB1 Signaling Pathway in Nonalcoholic Fatty Liver Disease.骨桥蛋白通过激活非酒精性脂肪性肝病中的JAK1/STAT1/HMGB1信号通路促进巨噬细胞M1极化。
J Clin Transl Hepatol. 2023 Apr 28;11(2):273-283. doi: 10.14218/JCTH.2021.00474. Epub 2022 May 31.
8
Targeting integrin pathways: mechanisms and advances in therapy.靶向整合素途径:机制与治疗进展。
Signal Transduct Target Ther. 2023 Jan 2;8(1):1. doi: 10.1038/s41392-022-01259-6.
9
Effective delivery of osteopontin small interference RNA using exosomes suppresses liver fibrosis TGF-β1 signaling.使用外泌体有效递送骨桥蛋白小干扰RNA可抑制肝纤维化转化生长因子-β1信号传导。
Front Pharmacol. 2022 Sep 2;13:882243. doi: 10.3389/fphar.2022.882243. eCollection 2022.
10
Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy.靶向代谢相关脂肪性肝病(MAFLD)中程序性细胞死亡:一种有前途的新疗法。
Cell Mol Biol Lett. 2021 May 7;26(1):17. doi: 10.1186/s11658-021-00254-z.